Treatment results of COVID-19 patients with Molnupiravir in Long An province in 2021

Abstract

Molnupiravir is an orally-administered, small-molecule, antiviral prodrug that inhibits the replication of RNA viruses through viral error induction. On August 25, 2021, the Viet Nam Ministry of Health deployed a pilot program of the antiviral drug Molnupiravir to control the treatment of COVID-19 cases at home and in the community in 46 provinces (affected by COVID-19 epidemic) across the country with 300,000 doses of the drug. We conducted a study to evaluate the real-world safety and effectiveness of Molnupiravir on COVID-19 patients treated at home and
in the community in Long An province. A multicenter, retrospective cohort study was conducted at hospitals and commune health centres in Long An province. 1085 patients being treated with Molnupiravir were included. Molnupiravir adverse event rate was 2,7%. The rate of progression getting worse was 0.3%, the cure rate was 99.8%, the death rate was 0%, and the rate of viral clearance after 5 days of treatment was 93.1%. The study concluded that Molnupiravir was safe and effective in the treatment of asymptomatic-to-moderate COVID-19 in Long An province.